Emicizumab should be prescribed independent of immune tolerance induction

di Le Quellec, Sandra, Negrier, Claude
Pubblicato in Blood Adv (2018)

Dose tailoring of human cell line‐derived recombinant factor VIII simoctocog alfa: Using a limited sampling strategy in patients with severe haemophilia A

di Delavenne, Xavier, Dargaud, Yesim, Ollier, Edouard, Négrier, Claude
Pubblicato in Br J Clin Pharmacol (2019)

Evaluation of early musculoskeletal disease in patients with haemophilia: results from an expert consensus

di Seuser, Axel, Djambas Khayat, Claudia, Negrier, Claude, Sabbour, Adly, Heijnen, Lily
Pubblicato in Blood Coagul Fibrinolysis (2018)

Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia

di Monahan, Paul E., Négrier, Claude, Tarantino, Michael, Valentino, Leonard A., Mingozzi, Federico
Pubblicato in J Clin Med (2021)

Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives

di Young, Guy, Sørensen, Benny, Dargaud, Yesim, Negrier, Claude, Brummel-Ziedins, Kathleen, Key, Nigel S.
Pubblicazione 2013

Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab

di Dargaud, Yesim, Lienhart, Anne, Janbain, Maissaa, Le Quellec, Sandra, Enjolras, Nathalie, Negrier, Claude
Pubblicato in Haematologica (2018)

Impaired factor XIII activation in patients with congenital afibrinogenemia

di Bridey, Françoise, Négrier, Claude, Duval, Cedric, Ariëns, Robert, de Moerloose, Philippe, Casini, Alessandro
Pubblicato in Haematologica (2019)

Reccurrent F8 Intronic Deletion Found in Mild Hemophilia A Causes Alu Exonization

di Jourdy, Yohann, Janin, Alexandre, Fretigny, Mathilde, Lienhart, Anne, Négrier, Claude, Bozon, Dominique, Vinciguerra, Christine
Pubblicato in Am J Hum Genet (2018)

Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with Inhibit...

di Brackmann, Hans H., Schramm, Wolfgang, Oldenburg, Johannes, Cano, Viridiana, Turecek, Peter L., Négrier, Claude
Pubblicato in Hamostaseologie (2020)

MDA-9/Syntenin Is Essential for Factor VIIa-induced Signaling, Migration, and Metastasis in Melanoma Cells

di Aissaoui, Hanaa, Prévost, Célia, Boucharaba, Ahmed, Sanhadji, Kamel, Bordet, Jean-Claude, Négrier, Claude, Boukerche, Habib
Pubblicato in J Biol Chem (2015)

MDA-9/Syntenin is essential for factor VIIa-induced signaling, migration, and metastasis in melanoma cells.

di Aissaoui, Hanaa, Prévost, Célia, Boucharaba, Ahmed, Sanhadji, Kamel, Bordet, Jean-Claude, Négrier, Claude, Boukerche, Habib
Pubblicato in J Biol Chem (2015)

Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis

di Mancuso, Maria Elisa, Reding, Mark T., Negrier, Claude, Kerlin, Bryce A., Rangarajan, Savita, Simpson, Mindy L.
Pubblicato in Thromb Haemost (2021)

Alpha Cyano-4-Hydroxy-3-Methoxycinnamic Acid Inhibits Proliferation and Induces Apoptosis in Human Breast Cancer Cells

di Hamdan, Lamia, Arrar, Zoheir, Al Muataz, Yacoub, Suleiman, Lutfi, Négrier, Claude, Mulengi, Joseph Kajima, Boukerche, Habib
Pubblicazione 2013

Why patients with THBD c.1611C>A (p.Cys537X) nonsense mutation have high levels of soluble thrombomodulin?

di Jourdy, Yohann, Enjolras, Nathalie, Le Quellec, Sandra, Bordet, Jean Claude, Négrier, Claude, Vinciguerra, Christine, Dargaud, Yesim
Pubblicato in PLoS One (2017)

Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients

di Santagostino, Elena, Negrier, Claude, Klamroth, Robert, Tiede, Andreas, Pabinger-Fasching, Ingrid, Voigt, Christine, Jacobs, Iris, Morfini, Massimo
Pubblicazione 2012

A French multicenter randomised trial comparing two dose-regimens of prothrombin complex concentrates in urgent anticoagulation reversal

di Kerebel, Delphine, Joly, Luc-Marie, Honnart, Didier, Schmidt, Jeannot, Galanaud, Damien, Negrier, Claude, Kursten, Friedrich, Coriat, Pierre
Pubblicazione 2013

Global Post-Authorization Safety Surveillance Study: real-world data on prophylaxis and on-demand treatment using FEIBA (an activated prothrombin complex concentrate)

di Negrier, Claude, Voisin, Sophie, Baghaei, Fariba, Numerof, Robert, Novack, Aaron, Doralt, Jennifer E., Romanov, Vadim, Gringeri, Alessandro
Pubblicato in Blood Coagul Fibrinolysis (2016)

Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study

di Schmitt, Christophe, Adamkewicz, Joanne I., Xu, Jin, Petry, Claire, Catalani, Olivier, Young, Guy, Negrier, Claude, Callaghan, Michael U., Levy, Gallia G.
Pubblicato in Thromb Haemost (2021)

Hypofibrinolytic state and high thrombin generation may play a major role in SARS‐COV2 associated thrombosis

di Nougier, Christophe, Benoit, Remi, Simon, Marie, Desmurs‐Clavel, Helene, Marcotte, Guillaume, Argaud, Laurent, David, Jean Stephane, Bonnet, Aurelie, Negrier, Claude, Dargaud, Yesim
Pubblicato in J Thromb Haemost (2020)

Characterization of an autosomal dominant bleeding disorder caused by a thrombomodulin mutation

di Dargaud, Yesim, Scoazec, Jean Yves, Wielders, Simone J. H., Trzeciak, Christine, Hackeng, Tilman M., Négrier, Claude, Hemker, H. Coenraad, Lindhout, Theo, Castoldi, Elisabetta
Pubblicato in Blood (2015)